- Home
- JZXN vs IMRN Comparison
JZXN vs IMRN Comparison
Compare JZXN & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- IMRN
- Stock Information
- Founded
- JZXN 2017
- IMRN 1994
- Country
- JZXN China
- IMRN Australia
- Employees
- JZXN N/A
- IMRN N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- JZXN Consumer Discretionary
- IMRN Health Care
- Exchange
- JZXN Nasdaq
- IMRN Nasdaq
- Market Cap
- JZXN 45.5M
- IMRN 10.1M
- IPO Year
- JZXN 2021
- IMRN N/A
- Fundamental
- Price
- JZXN $4.37
- IMRN $1.82
- Analyst Decision
- JZXN
- IMRN Strong Buy
- Analyst Count
- JZXN 0
- IMRN 1
- Target Price
- JZXN N/A
- IMRN $5.00
- AVG Volume (30 Days)
- JZXN 66.0K
- IMRN 3.4K
- Earning Date
- JZXN 01-01-0001
- IMRN 03-25-2025
- Dividend Yield
- JZXN N/A
- IMRN N/A
- EPS Growth
- JZXN N/A
- IMRN N/A
- EPS
- JZXN N/A
- IMRN N/A
- Revenue
- JZXN $1,400,139.00
- IMRN $4,048,286.00
- Revenue This Year
- JZXN N/A
- IMRN N/A
- Revenue Next Year
- JZXN N/A
- IMRN N/A
- P/E Ratio
- JZXN N/A
- IMRN N/A
- Revenue Growth
- JZXN N/A
- IMRN 82.90
- 52 Week Low
- JZXN $1.00
- IMRN $1.70
- 52 Week High
- JZXN $67.60
- IMRN $3.09
- Technical
- Relative Strength Index (RSI)
- JZXN 55.79
- IMRN 44.61
- Support Level
- JZXN $3.04
- IMRN $1.75
- Resistance Level
- JZXN $5.49
- IMRN $2.07
- Average True Range (ATR)
- JZXN 0.80
- IMRN 0.12
- MACD
- JZXN -0.08
- IMRN -0.00
- Stochastic Oscillator
- JZXN 54.29
- IMRN 29.47
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.